You are here ยป News


July 20, 2016

Lausanne (Switzerland) - Osaka (Japan), July 20, 2016 – Maruho Co., Ltd. (“Maruho”, Headquarters: Osaka, Japan, President and CEO: Koichi Takagi), and Galderma Pharma S.A. (”Galderma SA”, Headquarters: Lausanne, Switzerland, CEO: Stuart Raetzman), announced on January 18, 2016 that they agreed to enter into a comprehensive set of agreements to strengthen their strategic alliance focused on the development and commercialization of prescription drugs for dermatology in Japan, including, but not limited to, therapies in the fields of acne and rosacea. Currently, specific initiatives based on the agreements have been actively promoted by both companies. The latest developments are outlined as follows in the points below. Maruho, Galderma SA and Galderma KK (“Galderma KK” Head Office: Shinjuku, Tokyo, President and CEO: Leslaw Rudy) are working to contribute to the treatment of patients suffering from skin diseases by strengthening the portfolio of therapeutic agents for skin disorders available in Japan and empowering healthcare professionals with these new treatment options.

1. After 14 years since July 2002, the sales and marketing departments of Galderma KK’s prescription medicine sales business will end their business in July 2016. After this, based on the strategic alliance between Maruho and Galderma SA, Maruho will market and provide information for Galderma’s products in Japan. Galderma KK will focus its commercial activities on Aesthetic & Corrective and Self-medication fields.

2. Shionogi & Co., Ltd. (“Shionogi” Head Office: Osaka, Japan, President and CEO: Isao Teshirogi, Ph.D) previously marketed Galderma KK’s acne vulgaris treatment “Differin® Gel 0.1%” (“Differin” INN: adapalene). Shionogi’s contract with Galderma KK ended on July 16, 2016. Maruho inherited the marketing rights in Japan for Differin on July 17, 2016 and will start marketing the product from July 26, 2016.

3. In order to further strengthen the strategic alliance between Maruho and Galderma SA, on June 28, 2016 Maruho and Galderma SA signed an agreement to transfer marketing rights and manufacturing and marketing authorization to Maruho for two prescription products owned by Galderma KK. Anti-fungal agent “Pekiron® Cream 0.5%” (“Pekiron” INN: amorolfine hydrochloride) and reduction of malodor generated in cancerous cutaneous ulcers treatment “Rozex® Gel 0.75%” (“Rozex” INN: metronidazole). In accordance, Maruho will begin activities to provide pharmaceutical information for these products from August 1, 2016 and plans to proceed in stages for the transfer of marketing rights and manufacturing and marketing authorization.

4. On July 4, 2016, Galderma KK received manufacturing and marketing approval in Japan for the topical treatment for acne vulgaris, Epiduo® Gel (“Epiduo” INN: 2.5% benzoyl peroxide and 0.1% adapalene). In accordance with the strategic alliance between the two companies, Maruho will market this product and provide pharmaceutical information in Japan from November 2016.

About Galderma
Dating back to 1961, Galderma is now present in 100 countries with an extensive product portfolio to treat a range of dermatological conditions. The company partners with health care professionals around the world to meet the skin health needs of people throughout their lifetime. Galderma is a leader in research and development of scientifically-defined and medically-proven solutions for the skin, hair and nails.
For more information, please visit

About Maruho
Maruho Co., Ltd. has its headquarters in Osaka and leads Japan in research and development, manufacturing, and commercialization of dermatological products. Founded in 1915, Maruho has 1,335 employees (as of the end of September 2015), and net sales were approximately 67.0 billion yen in the previous fiscal year. Pursuing its long-term corporate vision of “Excellence in Dermatology,” Maruho is striving to improve the health and quality of life of people all over the world.
For more information, please visit

About Differin®
A gel formulation containing 0.1% of the active ingredient adapalene, Differin is indicated for the treatment of acne vulgaris. Differin was approved in Japan in 2008 and marketed by Galderma KK and Shionogi & Co., Ltd. It is currently approved in more than 80 countries.

About Pekiron®
A cream formulation containing 0.5% of the active ingredient amorolfine hydrochloride, Pekiron is an anti-fungal agent indicated for the treatment of dermatomycosis. In 1993 Kyorin Pharmaceutical Co., Ltd. received manufacturing and marketing approval, then marketed the product in Japan. In February 2013, Galderma KK inherited manufacturing and marketing rights.

About Rozex®
A gel formulation containing 0.75% of the active ingredient, metronidazole, Rozex was the first drug in Japan approved with the indication of “Reduction of malodor generated in cancerous cutaneous ulcers”. In December 2010, Galderma KK developed Rozex at the request of the Ministry of Health, Labour and Welfare. Galderma KK received manufacturing and marketing approval in December 2014, then began marketing the product in May 2015. It is approved for this indication in Japan and the United Kingdom.

A gel formulation of a combination drug indicated for the treatment of acne vulgaris containing 2.5% benzoyl peroxide and 0.1% adapalene. Galderma KK received manufacturing and marketing approval for Epiduo in Japan in July 2016. In the US it was approved in 2008 and launched in 2009. In France it was approved and launched in 2008 and is used widely in western countries. 

Contact Information:
Yvan Deurbroeck, Global Vice President Communications
Mobile phone +41792543824

Maruho Co., Ltd.
Public Relations Department
Roger Matthews
Tel: +81-(0)6-6371-8831  Fax: +81-(0)6-6376-1724

Posted in: Press release

Follow us Follow us on twitter Follow us on Linkedin

Corporate responsibility

Growing a responsible dermatological community

Discover some of the positive initiatives we are involved in across the world



We are committed

See all videos